Stock events for MetaVia, Inc. (MTVA)
MetaVia's stock has declined approximately 75% since September 30, 2025. The company executed a 1-for-11 reverse stock split in December 2025 to regain Nasdaq compliance. MetaVia announced and closed $8.1 million and $9.3 million underwritten public offerings in January 2026, diluting existing shareholders. The company reported positive statistically significant results from its Phase 1b clinical trial of DA-1726 in metabolic disease. MetaVia announced positive AI-modeling results from its collaboration with Syntekabio in February 2026. The company presented new Phase 2a data on vanoglipel and new Phase 1 and pre-clinical data on DA-1726 at various conferences.
Demand Seasonality affecting MetaVia, Inc.’s stock price
The provided information does not contain specific details regarding demand seasonality for MetaVia, Inc.'s products and services, as its primary focus is on research and development with products still in clinical trials.
Overview of MetaVia, Inc.’s business
MetaVia, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases, including obesity and MASH. Their lead programs include DA-1726, in Phase 1 trials for obesity, and DA-1241 (vanoglipel), in Phase 2a clinical trials for MASH. MetaVia also has therapeutic programs for COVID-19, diabetic neuropathy, cognitive impairment, and dyslipidemia, and maintains strategic partnerships with Pfizer Inc. and Dong-A ST. The company was formerly known as NeuroBo Pharmaceuticals Inc. until November 2024.
MTVA’s Geographic footprint
MetaVia Inc. is headquartered in Cambridge, Massachusetts, United States. The company has a manufacturing collaboration with Dong-A ST, indicating an international partnership for production.
MTVA Corporate Image Assessment
The provided information does not offer a direct assessment of MetaVia, Inc.'s brand reputation in the past year. However, stock events like the reverse stock split and dilutive public offerings could negatively impact investor perception, while positive clinical trial results and scientific presentations would generally contribute positively to its reputation within the scientific and medical communities.
Ownership
The provided search results do not explicitly detail major institutional and individual owners of MetaVia, Inc.
Ask Our Expert AI Analyst
Price Chart
$1.51
